What's new?
16/05/2019

Oversubscribed round to bring first products powered by enzymatic DNA synthesis technology to market

Paris, May 16, 2019. Sofinnova Partners, a leading European venture capital firm specialized in the life sciences, today announced that its portfolio company DNA Script, an industry leader in the manufacturing of synthetic nucleic acids using proprietary enzymatic technology, has raised $38.5 million in Series B financing. New shareholders LSP and BPIFrance joined the round, alongside existing shareholders Kurma Partners, Idinvest Partners, Illumina Ventures, and M Ventures (the corporate venture arm of Merck KGaA). Sofinnova Partners was the first institutional investor in DNA Script in 2016.

DNA Script is the world’s leading company in manufacturing synthetic nucleic acids using enzymatic technology. Founded in 2014 in Paris, the company aims to accelerate innovation in life sciences and technology delivering rapid, affordable, and high-quality DNA. Sixty years after the discovery of DNA, DNA Script’s revolutionary approach leverages billions of years of nature’s evolution in synthesizing DNA to enable genome scale synthesis.

The company offers a novel biochemical process for DNA and RNA synthesis, a fundamental tool used in biology research. At a recent academic conference, DNA Script presented its ability to synthesize 200nt of DNA with remarkable accuracy. This innovation may be used in numerous applications, including electronic data storage, by leveraging unprecedented capabilities of the molecule to store information. The fundraising allows DNA Script to further develop its unique enzymatic technology and nucleotide chemistry platform, and deliver the promise of same-day results.

Joško Bobanović, Partner at Sofinnova Partners, said: “We are excited that DNA Script, which we have backed from its first round of financing, was able to raise such a significant round. The company continues to deliver on its plan, and is now funded by a group of likeminded investors who support the team’s vision of creating a business that enables new applications for synthetic DNA and RNA in areas including drug discovery and development, agriculture, and industrial and food technologies.”

“Sofinnova Partners has been an excellent partner from a very early stage, just after the inception of our company,” said Thomas Ybert, CEO of DNA Script. “Since then, they have helped us on a daily basis to build DNA Script from the ground up. The team brings a strong expertise in the technology as well as one of the broadest global networks in the industry. Importantly, they also provide unconditional support and coaching to our entrepreneurs – whatever the challenge at hand,” he said.

This new funding reaffirms Sofinnova Partners’ investment strategy in the industrial biotech field, initiated in 2009. As a pioneer in this emerging and rapidly growing sector, Sofinnova Partners has a portfolio of 14 industrial biotech companies, backed through two dedicated funds: Sofinnova Green Seed Fund, which raised €22.5M in 2012, and Sofinnova IB I, which raised €125M in 2017.

About DNA Script
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims to accelerate innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script’s approach leverages billions of years of natural evolution to enable genome-scale synthesis. The company’s technology has the potential to greatly accelerate the development of new therapeutics, enhanced diagnostics, sustainable chemical production, improved crops and DNA data storage.
www.dnascript.co

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Headquartered in Paris, France, the firm brings together a team of professionals from all over Europe, the U.S. and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information: http://sofinnovapartners.com/.

Press contact for Sofinnova Partners

International
Kate Barrette
RooneyPartners LLC
kbarrette@rooneyco.com

France
Anne Rein
S&I
+ 33 6 03 35 92 05
anne.rein@strategiesimage.com

10/07/2015

Sofinnova Partners Renewable Chemistry Start-up Award, presented at Bio World Congress on Industrial Biotechnology, recognises the most promising renewable chemistry start-up. The Top 5 companies have been selected by popular vote online and the winner will be selected at Bio World Congress on Industrial Biotechnology by an industry jury. – RESULTS HERE !

The Renewable Chemistry Start-Up Award is supported by Sustainability Consult, the leading agency for bio-economy communications and public relations.

10/07/2015

Sofinnova Partners Renewable Chemistry Start-up Award, presented at Bio World Congress on Industrial Biotechnology, recognises the most promising renewable chemistry start-up. The Top 5 companies have been selected by popular vote online and the winner will be selected at Bio World Congress on Industrial Biotechnology by an industry jury. – RESULTS HERE !

The Renewable Chemistry Start-Up Award is supported by Sustainability Consult, the leading agency for bio-economy communications and public relations.

24/06/2014

10-12 December 2014
Four Seasons, Prague, Czech Republic

Veleslavínova 1098/2a
110 00 Praha 1-Staré Mesto
Czech Republic

bohemian_summit2014

This invitation-only conference for senior executives from medical device companies in Europe, provides a private and exclusive setting for networking and partnering. The agenda will include high-level panel discussions with keynotes from industry and academic leaders, as well as social networking events.

Who Attends?
Attendance to the Bohemian Medical Device Summit is by invitation only. Invitations are limited to CEOs and senior executives from medical technology companies and senior executives with responsibility for R&D, Licensing, M&A and Business Development from major medical device manufacturers. The conference is NOT open to service providers, such as CROs, data support, consultancy companies, banks, law firms, VCs, or funding companies.

http://www.bohemiansummit.com/

24/06/2014

10-12 December 2014
Four Seasons, Prague, Czech Republic

Veleslavínova 1098/2a
110 00 Praha 1-Staré Mesto
Czech Republic

bohemian_summit2014

This invitation-only conference for senior executives from medical device companies in Europe, provides a private and exclusive setting for networking and partnering. The agenda will include high-level panel discussions with keynotes from industry and academic leaders, as well as social networking events.

Who Attends?
Attendance to the Bohemian Medical Device Summit is by invitation only. Invitations are limited to CEOs and senior executives from medical technology companies and senior executives with responsibility for R&D, Licensing, M&A and Business Development from major medical device manufacturers. The conference is NOT open to service providers, such as CROs, data support, consultancy companies, banks, law firms, VCs, or funding companies.

http://www.bohemiansummit.com/

02/05/2014

Women Innovating Together in Healthcare is a vibrant network of accomplished women who have talent in industry, medicine, research, charity and finance. Members share a deep knowledge of the life sciences and an admirable track record of success. We come together from complementary backgrounds for lively debate, inspiration, discussion of challenges, and laughter.
with-logo

02/05/2014

Women Innovating Together in Healthcare is a vibrant network of accomplished women who have talent in industry, medicine, research, charity and finance. Members share a deep knowledge of the life sciences and an admirable track record of success. We come together from complementary backgrounds for lively debate, inspiration, discussion of challenges, and laughter.
with-logo